biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal
Phase 3 · small molecule · Schizophrenia
Valbenazine (NBI-98854-ATS3019) is an oral small-molecule therapeutic candidate being developed by Neurocrine Biosciences for schizophrenia as an adjunctive treatment. The program is currently in Phase 3 development, with an active randomized, double-blind, placebo-controlled trial evaluating efficacy, safety, and tole
Internal code NBI-98854-ATS3019
Valbenazine (NBI-98854-ATS3019) is an oral small-molecule therapeutic candidate being developed by Neurocrine Biosciences for schizophrenia as an adjunctive treatment. The program is currently in Phase 3 development, with an active randomized, double-blind, placebo-controlled trial evaluating efficacy, safety, and tolerability. Valbenazine itself has already received FDA approval via Sandoz Inc (ANDA215962), indicating the molecule has established regulatory precedent. The current Phase 3 trial (NCT 2023-508433-14-00) represents Neurocrine's strategy to expand the clinical evidence base for valbenazine in schizophrenia, building on existing approvals. The mechanism of action and specific target remain not yet disclosed in available intelligence. This adjunctive approach positions valbenazine within a competitive landscape of established antipsychotics and emerging therapies. Key upcoming milestones include trial completion and potential regulatory submissions based on Phase 3 data.
Schizophrenia remains a significant unmet medical need despite the availability of multiple antipsychotic agents. Adjunctive treatment strategies that enhance efficacy or tolerability of existing antipsychotics represent an important clinical focus, as many patients experience inadequate symptom control or tolerability issues with monotherapy. Valbenazine's development as an adjunctive agent addresses this gap by potentially offering clinicians an additional tool to optimize treatment outcomes in patients with suboptimal response to standard antipsychotics.
The competitive landscape for schizophrenia treatment is crowded with established agents including aripiprazole, risperidone, olanzapine, clozapine, paliperidone, and others. However, the adjunctive indication represents a distinct market segment focused on treatment-resistant or partially responsive patients. Valbenazine's prior FDA approval through Sandoz provides regulatory and manufacturing precedent, potentially accelerating pathway to market if Phase 3 data support efficacy and safety in the schizophrenia adjunctive setting.
Commercial significance depends on Phase 3 trial success, competitive differentiation versus other adjunctive strategies, and market adoption among psychiatrists. The schizophrenia treatment market remains substantial, with significant patient populations globally experiencing inadequate symptom control despite current therapies.
Drug Class: Small-molecule antipsychotic adjunctive agent
Modality: Oral small-molecule
Route of Administration: Oral (capsule formulation)
Mechanism of Action: Not yet disclosed
Target: Not yet disclosed
Regulatory Status: Valbenazine has received FDA approval via Sandoz Inc under ANDA215962, establishing the molecule as an approved pharmaceutical entity. The current Phase 3 program by Neurocrine represents a new indication (adjunctive treatment in schizophrenia) or expanded clinical evidence base.
Related Therapies: Competitive agents in schizophrenia include established antipsychotics (aripiprazole, risperidone, olanzapine, clozapine, paliperidone, quetiapine, ziprasidone, lurasidone, brexpiprazole, amisulpride, asenapine, cariprazine) and emerging adjunctive approaches.
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 Adjunctive Schizophrenia Trial Active
Randomized, double-blind, placebo-controlled study evaluating efficacy, safety, and tolerability of valbenazine as adjunctive treatment in subjects with schizophrenia (NCT 2023-508433-14-00).
Valbenazine FDA Approval (Prior)
Valbenazine approved by FDA via Sandoz Inc under ANDA215962, establishing regulatory precedent for the molecule.
The schizophrenia treatment landscape includes multiple established antipsychotics with diverse mechanisms and formulations. First-generation agents (haloperidol, chlorpromazine, fluphenazine, perphenazine) and second-generation agents (aripiprazole, risperidone, olanzapine, quetiapine, ziprasidone, paliperidone, lurasidone, brexpiprazole, amisulpride, asenapine, cariprazine, clozapine) dominate the market. Emerging therapies include Indivior's PERSERIS, Vanda Pharmaceuticals' iloperidone, and investigational adjunctive approaches from Bright Minds Biosciences (minocycline, varenicline, clozapine formulations) and BioXcel Therapeutics (dexmedetomidine). Takeda markets ramelteon and vortioxetine for related psychiatric indications.
Valbenazine's positioning as an adjunctive agent differentiates it from monotherapy antipsychotics, targeting treatment-resistant or partially responsive patients. The molecule's prior FDA approval via Sandoz provides manufacturing and regulatory precedent, potentially offering advantages in development speed and manufacturing scale-up compared to novel entities. However, the adjunctive schizophrenia market remains relatively specialized compared to monotherapy segments, and clinical differentiation versus existing adjunctive strategies will be critical for commercial success.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PERSERIS | Indivior Pty Ltd | small_molecule | approved |
| Iloperidone | Vanda Pharmaceuticals Netherlands B.V. | small_molecule | approved |
| Paliperidone ER | Hospital Authority, Hong Kong | small_molecule | approved |
| Valbenazine | NEUROCRINE BIOSCIENCES INC | small_molecule | approved |
| Minocycline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Varenicline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| SULPIRIDE , QUETIAPINE , PERPHENAZINE , CLOTIAPINE , ZIPRASIDONE , HALOPERIDOL , SERTINDOLE , PALIPERIDONE , ZUCLOPENTHIXOL , CARIPRAZINE , LEVOMEPROMAZINE , LURASIDONE , BREXPIPRAZOLE , AMISULPRIDE , CLOZAPINE , CHLORPROMAZINE , RISPERIDONE , FLUPHENAZINE , PROMAZINE , ARIPIPRAZOLE , ASENAPINE , OLANZAPINE , FLUPENTIXOL | Disc Medicine | small_molecule | approved |
| Aripiprazole | Otsuka Beijing Research Institute | small_molecule | approved |
| Ramelteon | Takeda | small_molecule | approved |
| Vortioxetine | Takeda | small_molecule | approved |
| Clozapine | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Dexmedetomidine | BioXcel Therapeutics | small_molecule | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Valbenazine has received FDA approval via Sandoz Inc (ANDA215962), indicating the molecule is an approved pharmaceutical product. The current Phase 3 program by Neurocrine Biosciences represents either a new indication or expanded clinical evidence base for adjunctive use in schizophrenia. Regulatory pathway and expected submission timeline not yet disclosed.
European Union: EMA regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Future regulatory milestones depend on Phase 3 trial outcomes and Neurocrine's decision to pursue formal submissions in additional jurisdictions.
Valbenazine is being evaluated as an adjunctive (add-on) treatment for schizophrenia in patients who may have inadequate response to standard antipsychotics alone.
Yes, valbenazine has received FDA approval via Sandoz Inc (ANDA215962). The current Phase 3 trial by Neurocrine represents a new indication or expanded evidence base for adjunctive use in schizophrenia.
Neurocrine Biosciences Inc is sponsoring the Phase 3 trial (NBI-98854-ATS3019) evaluating valbenazine as adjunctive treatment in schizophrenia.
The mechanism of action for valbenazine in this indication has not yet been disclosed in available intelligence.
The specific molecular target of valbenazine has not yet been disclosed in available intelligence.
Valbenazine is administered orally as a capsule formulation.
The trial is in Phase 3, the final stage of clinical testing before regulatory submission, and is currently active.
The trial is a randomized, double-blind, placebo-controlled study comparing valbenazine to placebo as adjunctive treatment in subjects with schizophrenia.
The trial NCT identifier is 2023-508433-14-00.
The specific primary endpoints have not yet been disclosed in available intelligence.
The number of trial participants has not yet been disclosed in available intelligence.
Competitors include established antipsychotics (aripiprazole, risperidone, olanzapine, clozapine, paliperidone, quetiapine, ziprasidone, lurasidone, brexpiprazole, amisulpride, asenapine, cariprazine), emerging agents like Indivior's PERSERIS and Vanda's iloperidone, and adjunctive approaches from Bright Minds Biosciences and BioXcel Therapeutics.
The expected completion date for the Phase 3 trial has not yet been disclosed in available intelligence.
Many patients with schizophrenia experience inadequate symptom control or tolerability issues with monotherapy antipsychotics, creating a need for adjunctive treatment strategies to optimize outcomes in treatment-resistant or partially responsive patients.
No partner is disclosed for this program; Neurocrine Biosciences is the sole sponsor.
Success would establish Neurocrine in the adjunctive schizophrenia market, a segment with significant unmet medical need. Commercial success depends on Phase 3 efficacy/safety data, regulatory approval, and competitive differentiation versus alternative adjunctive strategies.
Regulatory status in Europe (EMA), Japan (PMDA), and China (NMPA) has not yet been disclosed in available intelligence.
NBI-98854-ATS3019 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Neurocrine's Phase 3 program for valbenazine in adjunctive schizophrenia represents a focused development strategy leveraging an already-approved molecule. This approach reduces development risk compared to novel entities and allows rapid advancement if Phase 3 data support efficacy and safety. Success would establish Neurocrine in the schizophrenia adjunctive treatment market, a segment with significant unmet medical need among treatment-resistant patients.
Competitive Implications: Valbenazine would enter a competitive adjunctive schizophrenia market alongside emerging therapies from Bright Minds Biosciences and BioXcel Therapeutics. Clinical differentiation in efficacy, safety, tolerability, and pharmacokinetics will determine market positioning. The molecule's prior FDA approval provides manufacturing and regulatory advantages versus novel competitors.
Future Catalysts: Phase 3 trial completion and data readout represent the primary near-term catalyst. Positive efficacy and safety data could support regulatory submissions in the United States and potentially other jurisdictions. Negative or neutral data would likely halt development. Post-approval, market adoption among psychiatrists and payers will depend on clinical evidence, pricing, and competitive positioning versus alternative adjunctive strategies.
Expected Milestones: Phase 3 trial completion timeline not yet disclosed. Regulatory submission pathway and expected approval timeline remain unknown pending trial outcomes.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.